TNF and benign prostatic hyperplasia: In the prostate, similar results of IL-8 and TNF-α level were shown, of which the high-dose XLQ-treated group (89.86 ± 6.65 ng/mg and 9.91 ± 0.63 pg/mg, respectively, P<0.01; Figure 2(a)) decreased the most significantly, compared to the model of BPH group (174.04 ± 5.24 ng/mg and 18.26 ± 0.81 pg/mg, respectively) and finasteride-treated group (126.06 ± 7.52 ng/mg and 12.41 ± 0.81 pg/mg, respectively, P<0.01).